Amylyx is dipping back into the well to raise funds to launch its recently approved ALS drug Relyvrio. The company plans to offer 6 million shares in a public offering to bring in between $167 to $192.2 million.
If you are not happy with the results below please do another search
50 search results for:
Leo Tarkovsky brings more than 25 years of proven experience scaling companies in the healthcare space.
Cancer immunotherapy biotech OncoSec Medical Inc. will lay off around 45% of its workforce to focus its resources on the development of its lead asset, TAVO-EP (tavokinogene telseplasmid), the company announced Tuesday.
Biohaven Pharmaceuticals has set a new course following its acquisition by Pfizer with a focus on developing therapeutics that modulate the Kv7 ion channel for the treatment of neurological and neuropsychiatric diseases.
The world’s largest dialysis company is seeking out kidney disease patients long before they need the most acute form of care as it plans for growth of new drugs that attack the condition’s causes early on.
Intravacc will develop a prophylactic vaccine based on its proprietary outer membrane vesicles (OMV) platform technology.
Biden, doctors say new abortion laws have chilling impact By Nandita Bose WASHINGTON, Oct 4 (Reuters) – U.S. President Joe Biden and top White House officials announced new guidelines and grants to protect abortion and contraception rights on Tuesday, and said women’s rights have already been curtailed since the Supreme Court overturned Roe vs. Wade […]
The U.S. Centers for Disease Control and Prevention (CDC) on Tuesday estimated that nearly 13% of the circulating coronavirus variants in the United States were of the BA.4.6 subvariant of Omicron, as of the week ended Oct. 1.
Obstetricians, gynecologists, other medical professionals, and abortion rights advocates petitioned the U.S. Food and Drug Administration (FDA) on Tuesday to urge Danco Laboratories to seek approval of mifepristone, a pill used in terminating early pregnancies at home, for miscarriage management.
Bristol Myers Squibb entered two separate research collaboration and licensing deals, one with San Francisco-based SyntheX and the second with London’s Autolus Therapeutics.